68

Business

Bavarian Nordic shares soar as massive cancer deal is signed

admin
March 4th, 2015


This article is more than 9 years old.

Agreement could potentially be worth 6.5 billion kroner

The Danish biotech company Bavarian Nordic has been on the rise since it announced that it was part of a co-operation aimed at developing an Ebola vaccine last year. And today, the company took another massive step towards long-term success.

Bavarian Nordic has revealed that it has signed an agreement with the American pharmaceutical company Bristol-Myers-Squibb (BMS) involving the exclusive option to license and commercialise its prostate cancer vaccine Prostvac.

“We are proud to partner with Bristol-Myers Squibb, whose excellence and leadership in immuno-oncology provides a strong foundation for advancing Prostvac, which has the potential to become an essential component in the treatment of prostate cancer,” Paul Chaplin, the CEO of Bavarian Nordic, said.

“Leveraging the capabilities of Bristol-Myers Squibb’s science, we look forward to exploring the full potential of Prostvac in the future treatment paradigm of prostate cancer.”

READ MORE: Bavarian Nordic part of US Ebola vaccine collaboration

Shares shoot up
The deal could potentially be worth 6.5 billion kroner and is the largest ever deal for the Danish company.

The agreement includes an option for BMS to launch and sell Prostvac over a certain period of time, depending on the results of the ongoing phase-3 studies.

The two companies have agreed that Bavarian Nordic will produce and distribute the vaccine.

Following the news of the deal today, Bavarian Nordic's share price shot up by close to 30 percent and is at its highest since the beginning of 2011.


Share

Most popular

Subscribe to our newsletter

Sign up to receive The Daily Post

















Latest Podcast

A survey carried out by Megafon for TV2 has found that 71 percent of parents have handed over children to daycare in spite of them being sick.

Moreover, 21 percent of those surveyed admitted to medicating their kids with paracetamol, such as Panodil, before sending them to school.

The FOLA parents’ organisation is shocked by the findings.

“I think it is absolutely crazy. It simply cannot be that a child goes to school sick and plays with lots of other children. Then we are faced with the fact that they will infect the whole institution,” said FOLA chair Signe Nielsen.

Pill pushers
At the Børnehuset daycare institution in Silkeborg a meeting was called where parents were implored not to bring their sick children to school.

At Børnehuset there are fears that parents prefer to pack their kids off with a pill without informing teachers.

“We occasionally have children who that they have had a pill for breakfast,” said headteacher Susanne Bødker. “You might think that it is a Panodil more than a vitamin pill, if it is a child who has just been sick, for example.”

Parents sick and tired
Parents, when confronted, often cite pressure at work as a reason for not being able to stay at home with their children.

Many declare that they simply cannot take another day off, as they are afraid of being fired.

Allan Randrup Thomsen, a professor of virology at KU, has heavily criticised the parents’ actions, describing the current situation as a “vicious circle”.

“It promotes the spread of viruses, and it adds momentum to a cycle where parents are pressured by high levels of sick-leave. If they then choose to send the children to daycare while they are still recovering, they keep the epidemic going in daycares, and this in turn puts a greater burden on the parents.”